Off and running

Off and running

Well 2016 has arrived and like past years the New Year starts with two very important conferences, the Consumer Electronics Show in Las Vegas followed by the J P Morgan HealthCare Conference in San Francisco.  This year as in the past there are several issues we’ll be paying very close attention too at both shows.

While most people think CES is all about big screen TV’s, drones and other way cool whiz bang gadgets the show has morphed over the years into a must attend event for anyone in healthcare. Each year Diabetic Investor has attended the healthcare pavilion has grown as the convergence of technology and healthcare continues. Last year wearables were all the rage, looking at the various releases we’ve seen for this year’s show that trend will continue.

The question is will these wearable cloud connected devices go beyond collecting data and then sending that data to the cloud. Will 2016 be the year when these way cool whiz bang devices become patient practical. Have companies learned that it’s no longer about data collection. That if this data is to impactful it must be turned into patient relevant information. Information that the patient can and will act upon.

Not to be redundant but if interconnected diabetes management (IDM) is ever to become the standard of care this evolution this transformation must occur. Given the events that transpired last year we sense that companies are beginning to realize this. That it’s no longer about way cool whiz bang cloud enabled. That it’s not about who has the best technology or hardware, rather who has the best system that transforms all this data into patient relevant patient actionable information.

When it comes to JPM Diabetic Investor is overly excited to attend this year. Will Sanofi (NYSE: SNY) announce the termination of their partnership with MannKind (NASDAQ: MNKD)? Will Lilly (NYSE: LLY) provide a glimpse of how they plan on marketing Basaglar, their biosimilar version of Lantus? Will AstraZeneca (NYSE: AZN) unveil a new strategy for their diabetes franchise? Which company or companies will emerge as THE next thing.

Based on the past this year’s conference should produce more than a few surprises.  This is what makes JPM another must attend event given as much, perhaps more is learned not in the presentations but all the scuttlebutt that takes place in the hallways, bars and restaurants.

Looking ahead Diabetic Investor isn’t sure what lies ahead for this wacky world in 2016. Each year just when it seems things can’t get any wackier something comes along to remind us that when it comes to the wacky world of diabetes anything no matter how crazy it may seem is not only possible but also plausible. Enjoy everyone 2016 is off and running.